AZNCF - Sangamo And Biogen Tie Up And Other News: The Good Bad And Ugly Of Biopharma
Sangamo Closes Gene Collaboration with Biogen
Sangamo Therapeutics (SGMO) reported that it has finalized its sale of stock to Biogen (BIIB), leading to the formal initiation of its global licensing collaboration with latter. The collaboration pertains to gene regulation therapies in neurology and their development and commercialization. These therapies are targeted towards ailments such as Parkinson’s, Alzheimer’s, neurological and neuromuscular diseases.
Under the terms and conditions of the collaboration, Sangamo has received $225 million in funds and is entitled to receive further upfront license fee of $125 million. The latter payment